Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...

Pfizer ( PFE 0.22%) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many income investors, questions about the sustainability of the dividend persist.

Pfizer › Pfizer (NYSE: PFE) has been a terrible investment over the past three years. Revenue and earnings have generally ...

Here is why Pfizer's newfound momentum could set the stock up to soar in 2026. Pfizer's generous dividend has become a big ...

The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...

If you are looking for dividend stocks, a good place to start is with unloved stocks like these, with yields of up to 6.4%.

Stellantis stock remains under pressure with declining margins and uncertain turnaround prospects. Click here to read an analysis of STLA stock now.

The Cubs acquired pitcher Mike Soroka from the Nationals for two prospects and reliever Andrew Kittredge from the Orioles for another prospect.

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation ...

Bristol-Myers Squibb (BMY) shares rise after beating Q2 forecasts, raising 2025 revenue outlook, and showcasing growth in key ...